EBITDA: Income before interest, taxes, depreciation and amortization.
Jyong Biotech Ltd. (MENS) had EBITDA of $-2.51M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-4.67M |
|
-- |
|
-- |
|
$2.61M |
|
$-2.61M |
|
$-2.06M |
|
$-4.67M |
|
$-4.67M |
|
$-4.67M |
|
$-4.67M |
|
$-4.67M |
|
$-4.67M |
|
$-2.61M |
|
|
EBITDA |
$-2.51M |
73.01M |
|
73.01M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$15.54M |
|
$3.09M |
|
$5.24M |
|
$20.78M |
|
$34.81M |
|
$10.16M |
|
$10.87M |
|
$45.68M |
|
$-24.91M |
|
$-24.91M |
|
$-24.91M |
|
76.03M |
|
| Cash Flow Statement Financials | |
$-3.04M |
|
$-13.51M |
|
$17.63M |
|
$0.10M |
|
$1.18M |
|
$1.08M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.45 |
|
-- |
|
-- |
|
-0.69 |
|
-0.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
18.75% |
|
18.75% |
|
-22.48% |
|
31.68% |
|
$-0.33 |
|
$-0.04 |
|
$-0.04 |
|